STOCK TITAN

CEL-SCI Corp - CVM STOCK NEWS

Welcome to our dedicated page for CEL-SCI news (Ticker: CVM), a resource for investors and traders seeking the latest updates and insights on CEL-SCI stock.

Overview

CEL-SCI Corp is a biotechnology company with a robust focus on immunotherapy and clinical research, specializing in the innovation and development of treatments designed to harness the human immune system. Established in 1983 and headquartered in Vienna, Virginia, the company has a longstanding history in researching advanced therapies to address cancer and a spectrum of infectious and autoimmune diseases. Utilizing its proprietary research platforms, CEL-SCI Corp develops investigational therapies with a goal to modulate immune responses and provide new approaches to medical treatment challenges. Its work is anchored in comprehensive drug discovery, rigorous clinical research protocols, and advanced development methods that target critical areas unmet by traditional therapeutic approaches.

Technology and Innovation

At the forefront of CEL-SCI Corp's operational model is its commitment to pioneering technology and innovative treatment strategies. The company has developed cutting-edge research platforms such as its unique Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented process that modulates T-cell responses. This technology is designed to stimulate the immune system to tackle a wide range of conditions including bacterial, viral, and parasitic infections, as well as autoimmune disorders. By integrating advanced immunological insights into its R&D process, CEL-SCI Corp positions itself as not only a developer of investigational therapies but as a contributor to the broader knowledge base within immunotherapy and drug development.

Product Pipeline and Research Focus

CEL-SCI Corp maintains a diverse suite of developmental candidates that target several high-need therapeutic areas. Its lead investigational product, Multikine, is undergoing advanced clinical trials aimed at treating head and neck cancers, reflecting the company’s commitment to addressing challenging oncological conditions. Alongside Multikine, the company is developing several other promising candidates through its LEAPS platform. These include product candidates that are tailored for the treatment of conditions such as rheumatoid arthritis and infectious diseases like COVID-19 and H1N1, as well as therapies related to transplantation and allergic reactions. Each candidate in the pipeline is underpinned by innovative technology that seeks to expand treatment possibilities and modulate immune responses in a controlled and effective manner.

Market Position and Collaborations

Within a competitive biotechnology landscape, CEL-SCI Corp differentiates itself through its deep-seated expertise in immunotherapy research and its strategic focus on complex diseases. Its research-driven approach is enhanced by key collaborations and partnerships, such as its agreement with the University of Georgia's Center for Vaccines and Immunology, which leverages academic and research excellence to further develop its product candidates. Such collaborations provide a multi-faceted perspective to clinical development and underscore the company’s commitment to high-quality, evidence-based research. This collaborative environment not only fuels innovative therapeutic solutions but also solidifies CEL-SCI Corp’s reputation as a key research entity in the sector.

R&D and Clinical Development

CEL-SCI Corp’s model emphasizes rigorous scientific inquiry and the execution of robust clinical trials. Its R&D framework is strategically structured to assess complex immunological mechanisms and translate these insights into actionable treatment solutions. The company's process involves extensive pre-clinical evaluations, followed by multi-phase clinical trials that rigorously test the safety and efficacy of its investigational products. Each step of this process is designed to ensure that its therapy candidates meet stringent regulatory and scientific standards, reinforcing the company’s overall commitment to excellence and credibility in the biotechnological arena.

Key Considerations

The company’s operations are characterized by a steadfast focus on addressing some of the most challenging medical conditions through scientific innovation. CEL-SCI Corp leverages its proprietary LEAPS platform to stimulate targeted T-cell responses, which are crucial for mounting effective defenses against various diseases. This targeted approach underscores a broader trend in pharmaceutical research where precision immunotherapy is becoming increasingly vital. Investors and stakeholders looking for insight into comprehensive drug development strategies will find CEL-SCI Corp a compelling study in how methodical research and strategic technology partnerships contribute to long-term research endeavors. The company’s broad portfolio of candidates not only reflects its technical versatility but also emphasizes its dedication to transforming immunotherapy research from the lab bench to potential clinical applications.

Conclusion

In summary, CEL-SCI Corp exemplifies the integration of advanced scientific research with dedicated clinical development. Its strategic focus on immunotherapy positions the company as a significant player in the biotechnology sector, with a diversified pipeline spanning cancer, infectious diseases, and autoimmune disorders. Through its innovative LEAPS technology and rigorous research methodologies, CEL-SCI Corp continues to contribute valuable insights and advancements in the field of therapeutic development, underlining its commitment to scientific excellence and the pursuit of novel treatment modalities.

Rhea-AI Summary
CEL-SCI Corporation (CVM) reported financial results and key clinical & corporate developments for Multikine® in head and neck cancer patients. Recent data presented at ESMO Congress showed a 73% survival rate with Multikine vs 45% in control, with a 28% absolute survival benefit. Statistically significant results with no safety concerns. Target population identified for regulatory filings, estimated at 145,000 global patients annually.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
-
Rhea-AI Summary
CEL-SCI Corporation (CVM) closes a public offering of 3,875,000 shares of common stock at $2.00 per share, raising $7.75 million for continued development of Multikine* and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.97%
Tags
-
Rhea-AI Summary
CEL-SCI Corporation (CVM) announces a public offering of 3,875,000 shares of common stock at $2.00 per share, aiming to raise $7.75 million for further development of Multikine and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.68%
Tags
Rhea-AI Summary
CEL-SCI Corporation completes the commissioning of its Multikine manufacturing facility, a key step in preparing for regulatory approval for the treatment of head and neck cancer. The facility has been expanded and upgraded in anticipation of filing a Biologics License Application with the FDA and other regulators. This achievement signifies a significant milestone in bringing Multikine to market, and the company's CEO emphasizes the high value of their manufacturing trade secret, capability, and know-how.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.48%
Tags
none
-
Rhea-AI Summary
CEL-SCI Corporation (NYSE American: CVM) has received a product-specific waiver from the European Medicines Agency (EMA) Paediatric Committee, allowing them to commercialize their cancer immunotherapy Multikine in the European Union. This waiver is a significant step forward for the company, as it eliminates a major hurdle in their path towards commercialization in Europe. The waiver ensures that the company does not face delays in their plans for commercialization. The EU Paediatric Regulation, enacted in 2007, aims to strengthen the investigation and development of medicinal products for the pediatric population. This regulatory change has a direct impact on CEL-SCI's ability to bring Multikine to the market in Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
-
Rhea-AI Summary
CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2023, as well as key clinical and corporate developments. The company identified the target head and neck cancer patient population for Multikine, which saw a 73% survival rate vs 45% in the control at 5 years. The UK's National Institute for Health and Care Excellence (NICE) selected Multikine to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck. Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression. Financially, research and development expenses decreased by 11% and general and administrative expenses decreased by 16%. Net loss narrowed by 12% to approximately $32.2 million for the twelve months ended September 30, 2023 from $36.7 million in fiscal 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
Rhea-AI Summary
CEL-SCI Corporation (CVM) announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck (SCCHN) in the UK. NICE posted a detailed report from the UK’s National Institute for Health and Care Research (NIHR) regarding Multikine, its clinical data, and its potential to become a better standard of care in treating newly diagnosed head and neck cancer in the UK.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.27%
Tags
none
-
Rhea-AI Summary
CEL-SCI Corporation (CVM) Announces Closing of $5 Million Public Offering for Cancer Immunotherapy Development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
-
Rhea-AI Summary
CEL-SCI Corporation (CVM) announced the pricing of an offering of 2,490,000 shares of its common stock at $2.00 per share, generating gross proceeds of approximately $5 million. The net proceeds will be used for the development of Multikine, general corporate purposes, and working capital. The offering is expected to close on November 20, 2023. ThinkEquity is the sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.57%
Tags
News
Rhea-AI Summary
CEL-SCI Corporation releases a shareholder letter from CEO Geert Kersten, detailing the efficacy of Multikine in head and neck cancer patients and plans for regulatory approval. The letter highlights the well-defined target population, the pre-surgical responses caused by Multikine, and the outstanding survival benefit. CEL-SCI believes they meet the necessary factors for approval and are eager to move forward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.26%
Tags
none

FAQ

What is the current stock price of CEL-SCI (CVM)?

The current stock price of CEL-SCI (CVM) is $0.2086 as of April 7, 2025.

What is the market cap of CEL-SCI (CVM)?

The market cap of CEL-SCI (CVM) is approximately 15.6M.

What is the core focus of CEL-SCI Corp?

CEL-SCI Corp specializes in immunotherapy research, developing investigational treatments primarily for cancer, infectious diseases, and autoimmune disorders through advanced R&D.

How does CEL-SCI Corp develop its therapies?

The company utilizes a combination of rigorous pre-clinical research and multi-phase clinical trials, leveraging its proprietary LEAPS technology to modulate immune responses effectively.

What is Multikine and how is it significant?

Multikine is CEL-SCI Corp's lead investigational immunotherapy, designed for the treatment of head and neck cancers, and is currently being evaluated in advanced clinical trials.

What role does the LEAPS platform play in the company’s pipeline?

LEAPS is a patented T-cell modulation process that forms the backbone of several product candidates, aiming to stimulate the immune system to fight a range of conditions including infections and autoimmune diseases.

How does CEL-SCI Corp position itself within the competitive biotechnology sector?

By emphasizing robust scientific research, strategic clinical development, and key collaborative partnerships, CEL-SCI Corp establishes its credibility and differentiates its innovative immunotherapy solutions in the market.

What therapeutic areas does CEL-SCI Corp target?

The company's research spans a variety of conditions including various cancers, infectious diseases such as COVID-19 and H1N1, rheumatoid arthritis, and other immunologically driven conditions.

How does CEL-SCI Corp ensure the credibility of its research?

CEL-SCI Corp employs rigorous clinical trials and thorough pre-clinical studies, following stringent regulatory guidelines and collaborating with academic research centers to validate its findings.

What distinguishes CEL-SCI Corp's approach to immunotherapy?

The company's use of its proprietary LEAPS technology to target T-cell modulation, combined with a diverse pipeline of treatment candidates, demonstrates its commitment to offering innovative and precise therapeutic solutions.
CEL-SCI Corp

NYSE:CVM

CVM Rankings

CVM Stock Data

15.57M
82.27M
2.26%
8.78%
6.87%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
VIENNA